Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Free Report) shares crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $3.88 and traded as high as $4.18. Ironwood Pharmaceuticals shares last traded at $4.06, with a volume of 1,124,162 shares changing hands.
Analyst Upgrades and Downgrades
A number of research firms have issued reports on IRWD. Wall Street Zen downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 5th. Weiss Ratings lowered shares of Ironwood Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, September 4th. Finally, Zacks Research lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $6.23.
Read Our Latest Stock Analysis on Ironwood Pharmaceuticals
Ironwood Pharmaceuticals Stock Performance
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.01). The company had revenue of $113.04 million during the quarter, compared to the consensus estimate of $114.84 million. Ironwood Pharmaceuticals had a net margin of 33.36% and a negative return on equity of 58.38%. Analysts forecast that Ironwood Pharmaceuticals, Inc. will post 1.1 earnings per share for the current year.
Insider Activity at Ironwood Pharmaceuticals
In other news, insider Ronald Silver sold 127,890 shares of the company’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $4.52, for a total transaction of $578,062.80. Following the completion of the transaction, the insider directly owned 313,680 shares of the company’s stock, valued at $1,417,833.60. This represents a 28.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 9.30% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Ironwood Pharmaceuticals
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Engineers Gate Manager LP boosted its stake in shares of Ironwood Pharmaceuticals by 22.8% during the 2nd quarter. Engineers Gate Manager LP now owns 98,052 shares of the biotechnology company’s stock worth $413,000 after buying an additional 18,200 shares during the last quarter. Squarepoint Ops LLC increased its position in shares of Ironwood Pharmaceuticals by 104.3% in the second quarter. Squarepoint Ops LLC now owns 66,899 shares of the biotechnology company’s stock valued at $282,000 after acquiring an additional 34,153 shares during the last quarter. AXQ Capital LP boosted its position in Ironwood Pharmaceuticals by 263.2% during the second quarter. AXQ Capital LP now owns 47,028 shares of the biotechnology company’s stock valued at $198,000 after purchasing an additional 34,079 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Ironwood Pharmaceuticals by 3.4% in the 2nd quarter. Wellington Management Group LLP now owns 468,821 shares of the biotechnology company’s stock valued at $1,974,000 after buying an additional 15,306 shares during the last quarter. Finally, Public Employees Retirement System of Ohio bought a new stake in Ironwood Pharmaceuticals during the second quarter worth $252,000.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a gastrointestinal-focused pharmaceutical company headquartered in Boston, Massachusetts. The company discovers, develops, and commercializes medicines for gastrointestinal diseases and other disorders where significant unmet medical needs remain.
Ironwood’s primary marketed product is LINZESS (linaclotide), an oral medication used to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The product was approved by the U.S.
Read More
- Five stocks we like better than Ironwood Pharmaceuticals
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
